EWTX

Edgewise Therapeutics, Inc.

EWTX · CIK 1710072 · Annual (10-K) · Last 5 years

Financial Trends

Revenue
20212025
Net Income−$168M
20212025
Operating CF−$144M
20212025
Free Cash Flow−$144M
20212025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Revenue—————
Cost of Revenue—————
Gross Profit—————
R&D Expense$0.2B$0.1B$0.1B$0.1B$0.0B
SG&A Expense—————
Operating Income$-0.2B$-0.2B$-0.1B$-0.1B$-0.0B
Net Income$-0.2B$-0.1B$-0.1B$-0.1B$-0.0B
EPS (Basic)$-1.63$-1.45$-1.57$-1.26$-1.14
EPS (Diluted)$-1.63$-1.45$-1.57$-1.26$-1.14

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Total Assets$0.6B$0.5B$0.3B$0.4B$0.3B
Current Assets$0.5B$0.5B$0.3B$0.4B$0.3B
Cash & Equivalents$0.1B$0.0B$0.1B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.5B$0.5B$0.3B$0.3B$0.3B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$-0.0B$-0.2B$0.1B$-0.1B$-0.2B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.2B$0.2B$0.1B$0.1B$0.2B
← Companies